Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), sold 200,000 shares of Class A Common Stock for approximately $904,000 on April 6, 2026, significantly reducing his direct holdings by 79.05% to 53,000 shares. This transaction, following the exercise of stock options, raised no particular concerns regarding market sentiment, as Wentworth still holds 700,000 stock options and retains a substantial interest in the company. Nuvation Bio, focused on oncology therapeutics, is navigating a challenging financial landscape with a net loss of around $204.6 million but has a promising pipeline of treatments, making it a stock suitable for long-term investors willing to take on risk.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/04/13/insider-sells-200k-shares-of-biotech-company-nuvation-bio-nuvb/
